Balentine LLC’s Exelixis EXEL Stock Holding History

Balentine LLC’s Portfolio EXEL Stock Details EXEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-648	Closed	-$15K	–	391
2020 Q2	$15K	Hold	648	–	–	﹤0.01%	453
2020 Q1	$11K	Buy	+648	New	+$11.9K	﹤0.01%	349

Other funds holding EXEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Balentine LLC's EXEL Position: Q3 2020 in Review

Balentine LLC sold out of Exelixis (EXEL) in Q3 2020, closing a stake of 648 shares — an estimated $15K sold.

Balentine LLC first reported a position in EXEL in Q1 2020 and held it in 2 quarters. The position peaked at $15K in Q2 2020. 367 funds tracked by Wall St. Rank hold EXEL as of Q3 2020.

Balentine LLC reported no remaining Exelixis position as of Q3 2020 after selling out during the quarter.
Balentine LLC sold 648 Exelixis shares in Q3 2020, an estimated $15K.
Balentine LLC first reported a position in Exelixis in Q1 2020 and held it in 2 quarters.
Balentine LLC's Exelixis position peaked at $15K in Q2 2020.
367 funds tracked by Wall St. Rank held Exelixis as of Q3 2020.

Based on Balentine LLC's 13F filing for Q3 2020, filed 2 Nov 2020.